Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628255 | 0.87 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL11041165 | 0.87 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL17201985 | 0.78 | USP2 (0.42) | USP2SLCO1B1LMNA | |
| SCHEMBL15536079 | 0.75 | USP2 (0.35) | USP2SLCO1B1 | |
| SCHEMBL3642844 | 0.75 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL2558949 | 0.75 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL2718998 | 0.75 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL3230568 | 0.75 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL455830 | 0.75 | USP2 (0.39) | USP2SLCO1B1 | |
| SCHEMBL3227090 | 0.75 | USP2 (0.39) | USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302721-A1 | ANTI-AGING EYE CREAM | L'OREAL (FR) | 2025-10-02 | — | — | US | claimed |
| WO-2025202997-A1 | AN ANTI-AGING EYE CREAM | L'OREAL (FR) | 2025-10-02 | — | — | WO | claimed |
| WO-2024069249-A1 | COMPOSITION BASED ON DEUTERIUM-DEPLETED WATER | KARIMI KARGAR MOJTABA (IR) | 2024-04-04 | — | — | WO | claimed |
| EP-3844233-B1 | CRYOGENIC, KINETICALLY ACTIVE FORMULATIONS AND SYSTEMS FOR THEIR DISPENSING | FORMULATED SOLUTIONS LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025202997-A1 | AN ANTI-AGING EYE CREAM | L'OREAL (FR) | 2025-10-02 | — | — | WO | disclosed |
| US-20250302721-A1 | ANTI-AGING EYE CREAM | L'OREAL (FR) | 2025-10-02 | — | — | US | disclosed |
| US-20250277274-A1 | MICROBIOME SIGNATURE | GIVAUDAN SA (CH) | 2025-09-04 | — | — | US | disclosed |
| EP-4593846-A1 | COMPOSITION BASED ON DEUTERIUM-DEPLETED WATER | Karimi-Kargar, Mojtaba (IR) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025096817-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN | L'OREAL (FR) | 2025-05-08 | — | — | WO | disclosed |
| US-20250134792-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN | L'OREAL (FR) | 2025-05-01 | — | — | US | disclosed |
| WO-2024229256-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-3265184-A1 | FERMENT EXTRACT OF EUPENICILLIUM CRUSTACEUM AND COSMETIC USE THEREOF | Lubrizol Advanced Materials, Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170333491-A1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING A BACTERIAL EXTRACELLULAR PRODUCT FROM PSEUDOALTEROMONAS ANTARCTICA, AND USE THEREOF | LIPOTEC, S.A.U. (ES) | 2017-11-23 | — | — | US | disclosed |
| EP-3212291-A1 | COSMETIC COMPOSITION CONTAINING HALOMONAS FERMENT EXTRACT, AND USE THEREOF | Lubrizol Advanced Materials, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212206-A1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING A BACTERIAL EXTRACELLULAR PRODUCT FROM PSEUDOALTEROMONAS ANTARCTICA, AND USE THEREOF | Lipotec, S.A.U (ES) | 2017-09-06 | — | — | EP | disclosed |
| US-20170224602-A1 | COSMETIC COMPOSITION CONTAINING HALOMONAS FERMENT EXTRACT, AND USE THEREOF | LUBRIZOL ADVANCED MATERIALS, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-3124033-A1 | POST-PROCEDURE WOUND HEALING SKIN CARE COMPOSITION | Zo Skin Health, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016066857-A1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING A BACTERIAL EXTRACELLULAR PRODUCT FROM PSEUDOALTEROMONAS ANTARCTICA, AND USE THEREOF | LIPOTEC, S.A.U. (ES) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016067218-A1 | COSMETIC COMPOSITION CONTAINING HALOMONAS FERMENT EXTRACT, AND USE THEREOF | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-9248160-B1 | Post-procedure skin care systems, compositions, and methods of use thereof | ZO SKIN HEALTH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250134792-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN | RBP4, CUTA, EPHB4 | USP2 3219/4885SLCO1B1 4267/4885LMNA 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.